

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

TOX/2025/21

Committee on the Toxicity of Chemicals in Food, Consumer Products and the Environment

Discussion paper on the effects of calcidiol supplementation during preconception, pregnancy and lactation

Introduction

1. In 2019, The Scientific Advisory Committee on Nutrition (SACN) agreed to conduct a risk assessment on nutrition and maternal health focusing on maternal outcomes during pregnancy, childbirth and up to 24 months after delivery; this would include the effects of chemical contaminants and excess nutrients in the diet.
2. SACN agreed that, where appropriate other expert Committees would be consulted and asked to complete relevant risk assessments e.g., in the area of food safety advice to support their review. Therefore, the Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment (COT) was asked to consider whether exposure to excess vitamin D would pose a risk to maternal health, as part of this review. A [Statement on the potential effects of excess vitamin D intake during preconception, pregnancy and lactation](#) was published by the COT in 2022. Following a discussion of the matter arising agenda item at the COT meeting of December 2022, the COT agreed that calcidiol should also be considered as an Annex to the [Statement on the potential effects of excess vitamin D intake during preconception, pregnancy and lactation](#). This was on the basis that calcidiol is a more potent form for vitamin D₂ and D₃ and its availability on the market is increasing.
3. The toxicity and biological function of vitamin D and its status in pregnancy has been discussed in the [Statement on the potential effects of](#)

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

[excess vitamin D intake during preconception, pregnancy and lactation](#) and therefore will not be discussed in detail in this paper.

Background

4. Calcidiol is a novel source of vitamin D₃ (cholecalciferol), which is formed via chemical synthesis from cholestatrienol (ACNFP, 2024). Calcidiol is also known as calcidiol monohydrate, 25-hydroxycholecalciferol monohydrate (25(OH)D₃ monohydrate) (EFSA, 2023), calcifediol or 25-hydroxyvitamin D (25(OH)D), with the latter two being the form used in supplementation (Biondi et al., 2017). Calcidiol is a synthetic form of 25(OH)D, which is an inactive precursor to the biologically active form of vitamin D known as 1,25-dihydroxyvitamin D (1,25 (OH)₂D) and thus is commonly referred to as a pre-hormone (Vieth, 2020).

5. Calcidiol has been assumed to be 2.5 times more bioavailable than vitamin D₃ (EFSA, 2023; ACNFP, 2024). Calcidiol is more hydrophilic and has a shorter half-life than cholecalciferol (vitamin D₃) (Navarro-valverde et al., 2016; Henríquez and Gómez de Tejada Romero, 2020; Donati et al., 2023). Calcidiol also causes a rapid increase in serum 25(OH)D levels (Navarro-Valverde et al., 2016; Maghbooli et al., 2021). This is due to differences in vitamin D₃ absorption and hydroxylation in the liver, with calcidiol not requiring bile acids, which results in faster and more efficient absorption into the systemic circulation (EFSA, 2022).

6. Calcidiol has been reported to be three to six times more potent in increasing serum 25(OH) D levels than supplemental vitamin D₃. This means that lower doses of calcidiol are required to achieve the same serum 25(OH)D levels as vitamin D₃ (Veith, 2020; Nishishinya, 2022). Other reports have showed 10 times more vitamin D₃ than calcidiol is needed to increase serum 25(OH)D levels to equivalent serum concentrations (Stamp et al., 1977). However, the COT did not consider either calcidiol or vitamin D₃ as being

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

more potent than the other as neither of these vitamin D derivatives are the active form of vitamin D (i.e. 1, 25 dihydroxyvitamin D).

7. As vitamin D and calcidiol are not equipotent there is no universal agreement by regulatory authorities on the conversion factor of calcidiol to vitamin D₃ in international units (IU) (Gázquez et al., 2022). However, conversion factors of 1.4- to 5-fold have been estimated by Cashman et al., 2012 and Rossini et al., 2005). The European Commission (EC) asked the European Food Safety Authority (EFSA) to derive a conversion factor for calcidiol to vitamin D₃ and the Panel on Nutrition, Novel Foods and Food Allergens (NDA) Panel derived a conversion factor of 5 that was established by the Panel on Additives and Products or Substances to convert calcidiol to vitamin D in animal Feed (EFSA, 2023a). EFSA also considered vitamin D equivalents (VDE) which is the expression of the “biological value of substances with vitamin D activity”. EFSA determined 1 µg of VDE to be equivalent to 0.4 µg of calcidiol, which in turn is equivalent to 40 IU.

8. However, after an updated exposure assessment in response to a request from EirGen Pharma Ltd to revise their previous opinion, EFSA proposed a conversion factor of 2.5 for the intake of calcidiol to VDE in December 2023, based on a systematic review of 10 randomised clinical trials (RCT). In these RCTs the effects of weekly and daily doses of calcidiol at 20 and 25 µg/day were compared to Vitamin D₃ on serum 25(OH)D levels over a 6-week period. At doses of 20 µg/day the mean relative bioavailability of calcidiol was 2.02-fold higher than vitamin D₃, whereas at 25 µg/day the mean relative bioavailability of calcidiol was 1.31-fold higher than vitamin D₃. However, the mean relative bioavailability of calcidiol was 2.4-fold higher than vitamin D₃ in EFSA’s meta-analysis including all available RCTs. In two RCTs that used reported doses of vitamin D₃ at 60 µg/day the mean relative bioavailability of calcidiol was 2.11-fold higher than vitamin D₃. (EFSA, 2024).

9. The UK Advisory Committee for Novel Foods and Processes (ACNFP) also agreed with EFSA’s conversion factor of 2.5 (ACNFP, 2024). Based on

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

the ACNFP review of a calcidiol application submitted by DSM Nutritional Products Ltd the FSA and FSS concluded calcidiol as “safe under the proposed conditions of use and does not pose a safety risk to human health” (ACNFP, 2024).

Toxicokinetics

10. Calcidiol has the same identity as the primary metabolite of vitamin D₃ which is 25-hydroxycholecalciferol, also known as calcifediol (ACNFP, 2024). In humans both vitamin D₂ and vitamin D₃ are converted into this primary metabolite in the liver, and then converted to 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃) in the kidneys and other tissues (Perez-Lopez et al., 2015).

11. Calcidiol is more hydrophilic and has a shorter half-life than vitamin D₃. The half-life of calcidiol has been reported by Barger-Lux et al., (1998) to be 19 days in a study in healthy young men and was estimated to be 13.4 days in healthy males aged 18-23 years by Jones et al., (2012). Vicchio et al., (1993) estimated a half-life of calcidiol of 10 days using a liquid chromatography/thermospray mass spectrometry method (Brandi and Minisola et al., 2013).

12. In their safety assessment of calcidiol as a novel food for use in food supplements, the ACNFP had not considered whether the use of calcidiol (a metabolite of vitamin D₃) would affect the downstream metabolism and homeostatic regulation of circulating vitamin D₃ metabolite levels. However, based on data submitted by DSM Nutrition Ltd it was concluded that “the applicant did not give reason to believe that 25-hydroxycholecalciferol” (also known as calcidiol) “as a novel food would be metabolised differently from 25-hydroxycholecalciferol coming from other dietary sources or via this pathway, or that it would have wider impacts on feedback regulation, related pathways or vitamin D homeostasis.” Ultimately, the ACNFP stated that calcidiol has the same identity as the endogenous metabolites of vitamin D₃ (i.e. 25-

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

hydroxycholecalciferol, calcifediol) and there is no evidence to suggest that they would behave differently in the body.

13. However, the ACNFP did note that information from literature suggested potential changes in metabolism in pregnant and lactating women (ACNFP, 2024). As discussed in the [Statement on the potential effects of excess vitamin D intake during preconception, pregnancy and lactation](#), “a number of studies have reported uniquely high levels of 1,25(OH)₂D during pregnancy; the conversion of 25(OH)D to 1,25(OH)₂D during the first trimester (12 weeks of pregnancy) results in a doubling of 1,25(OH)₂D levels, and that levels continue to rise 2- to 3-fold until delivery”. Although, this increase in 1,25(OH)₂D occurs without onset of hypercalciuria or hypercalcemia. Furthermore “the increase in 1,25(OH)₂D observed during pregnancy is not continued throughout lactation and “Pregnant women with normal placental function but non-functional renal enzyme 1- α -hydroxylase fail to increase circulating 1,25(OH)₂D₃ during pregnancy” (COT, 2022).

14. The ACNFP commented that data from literature supplied by the applicant reported serum 1,25(OH)₂D₃ levels to be similar in pregnant and lactating women in response to vitamin D supplementation were similar in pregnant and lactating women and in non-pregnant or non-lactating women (Institute of medicine, 2011).

Toxicity

15. As discussed in the [Statement on the potential effects of excess vitamin D intake during preconception, pregnancy and lactation](#) the main adverse effects from excessive amounts of all forms of vitamin D including calcidiol (COT, 2022) are hypercalcaemia and hypercalciuria. These adverse effects have been described as infrequent and often a result of doses higher than recommended guidelines and for long durations (Robbins et al., 2022).

16. The following studies discussed below were derived from multiple sources including an ACNFP Committee Advice Document (CAD), an EFSA

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

opinion on the “Safety of calcidiol monohydrate produced by chemical synthesis as a novel food pursuant to Regulation (EU) 2015/2283” (EFSA, 2021), and a literature search conducted by the FSA secretariat using the search terms listed on page 45.

Genotoxicity

17. The ACNFP reported the genotoxicity data submitted by the applicant (DSM Nutritional Products Ltd) in their assessment on the safety of calcidiol as a novel food for use in food supplements. A reverse mutation assay conducted in line with OECD test guideline (TG) No. 471 submitted by the applicant demonstrated calcidiol, at concentrations of 3, 10, 33, 100, 333, 1,000, 2,500, 5,000 µg/plate in experiment 1 and concentrations of 10, 33, 100, 333, 1,000, 2,500 and 5,000 µg/plate in experiment 2, did not increase the number of revertant colonies **in the presence and absence of metabolic activation** and therefore is not mutagenic (Wöhrle and Sokolowski, 2013).

18. The ACNFP also received further data from the applicant on an *in vitro* mutagenicity test which was conducted in line with OECD TG No. 490. Experiment 1 tested calcidiol at concentrations of up to 7.5 and 25 µg/ml in the presence and absence of S9 mix. In experiment 2 calcidiol was tested at concentrations of up to 5 µg/ml in the absence of S9 mix. Calcidiol was found to not be mutagenic in both experiments (Remus and Verspeek-Rip, unpublished report, 2016).

19. The applicant also submitted results of an *in vivo* micronucleus test to the ACNFP. The test was in line with OECD TG No. 474. Results showed no increase in micro nucleated erythrocytes in treated animals, indicating that the test substance was not genotoxic in this test (Verbaan and Remus, 2016). Further results submitted by the applicant to the ACNFP were from an *in vitro* chromosome aberration test conducted in line with OECD TG No. 473 (Weber and Schulz, 2005). In two experiments the highest concentration applied was 100 µg/mL of calcidiol. Neither experiment showed a statistically significant or biologically relevant increase in the number of cells carrying structural

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

chromosomal aberration. Calcidiol was therefore concluded not to be clastogenic (Weber and Schulz, 2005).

20. The studies discussed above (Wöhrle and Sokolowski, 2013; Weber and Schulz, 2005; and Verbaan and Remus, 2016) were also assessed by EFSA in their opinion on the “Safety of calcidiol monohydrate produced by chemical synthesis as a novel food pursuant to Regulation (EU)2015/2283”. Based on these genotoxicity studies EFSA concluded that calcidiol as a novel food was of no concern regarding genotoxicity (EFSA, 2021).

Animal studies

21. The following sub-chronic toxicity data obtained from primary research publications were also submitted to the ACNFP by DSM Nutritional Products Ltd in support of their application for calcidiol as a novel food for use in food supplements. It should be noted that these studies are proprietary and have not been published.

22. In a 14-day study, male rats were orally administered vitamin D₃ at doses at 10-fold intervals from 0.65 - 6,500 nmol or calcidiol in Wesson oil at doses of 0.46 - 4,600 nmol/day. The average daily doses were estimated to be 2.3 - 22,750 µg/kg bw/day for vitamin D₃ and 1.7 - 16,770 µg/kg bw/day, for calcidiol. Study authors reported “signs of excessive intake of vitamin D₃” were observed at doses of vitamin D₃ at 2,275 and 22,750 µg/kg bw/day and calcidiol at 16,770 µg/kg bw/day (Shepard and DeLuva, 1980). Death occurred in 9/10 rats administered vitamin D₃ at 22,750 µg/kg bw/day. Other adverse effects included reduced plasma phosphorus concentrations, hypercalcaemia and greyish-white mottling of the kidneys (consistent with calcification) at doses of vitamin D₃ at 2,275 µg/kg bw/day and calcidiol at 16,770 µg/kg bw/day.

23. In an unpublished 90-day study conducted in line with OECD TG No. 408, male and female rats received oral doses of calcidiol equivalent to 0, 7, 20, 60 and 180 µg/kg bw/day in a powdered formulation. The formulation also

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

contained antioxidant excipients of which many have biologically active potential which was not excluded given the absence of an excipient control. Mineralisation of the renal pelvis was observed in both sexes at doses of calcidiol of 20 µg/kg bw/day and above, and more specifically, 7 µg/kg bw/day in females. However, study authors did not consider this effect as adverse due to the absence of clinical chemistry findings indicating kidney dysfunction. Study authors therefore proposed an equivalent NOAEL of calcidiol of 180 µg/kg bw/day (ACNFP, 2024 citing Thiel et al., 2007).

24. Further analysis of the histopathological findings from this study by Hard, (2014) concluded that mineralisation is more common in rats than any other species of laboratory animals. Also, the pattern of mineralisation observed is inconsistent with that of hypercalcaemia due to excess vitamin D₃. Hard, (2014) attributed this inconsistency to the hygroscopic nature of the test substance and possibly the nature of excipients used in the study whose effects could not be excluded because of the lack of an excipient control in this study (ACNFP, 2024 citing Hard, 2014).

25. Based on the reported findings by Thiel et al., (2007), the ACNFP stated that “the mineralisation observed indicates disruption of kidney function at all doses in female rats and in all but the lowest dose in males. It is not, therefore, possible to derive a NOAEL from this study. If the lowest dose used, 7 µg/kg bw/day, which caused renal mineralisation in female rats only, is taken as a Lowest Observed Adverse Effect Level (LOAEL) this yields a margin of safety of 49 for a 70 kg adult ingesting 25-hydroxycholecalciferol at a dose of 10 mg/day or 21 for a 15 kg child taking 5 mg/day”. Ultimately, the ACNFP concluded that “given the human safety data provided, this provides sufficient reassurance for the use of 25-hydroxycholecalciferol at the proposed doses in humans” (ACNFP, 2024).

Human studies and case reports

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

26. EFSA reviewed the safety of calcidiol monohydrate as a novel food intended for use in food supplements in 2021 and they reported that in adults supplementing with 10 µg/day (as a novel food), their serum 25(OH)D levels remained below 200 nmol/L, which is considered to be in the normal range of 25 - 200 nmol/L (COT, 2014). It should be noted that “circulating levels of 25(OH)D in the blood are normally in the range of 25-200 nmol/L (COT, 2014) but Hollis, 2005 reported circulating levels of 135 to 225 nmol/L in sunny environments where clothing or cultural practices do not prevent sun exposure (COT, 2014)”. (COT, 2022).

27. The ACNFP safety assessment on an application for calcidiol as a novel food for use in food supplements reported that “several trials have compared the effectiveness of Vitamin D₃ and 25- hydroxycholecalciferol” (ACNFP, 2024). The ACNFP further reported that “No intoxication as measured by hypercalcemia has been reported in humans at serum 25- hydroxycholecalciferol levels below 500 nmol/L (Heaney, 2008; and Hathcock et al., 2007).”

28. In a study with 116 healthy men that received calcidiol at doses of 10, 20 or 50 mg/day for a duration of 4 weeks, calcidiol was reported to be safe up to 50 mg/day. Treatment with calcidiol increased circulating serum 25(OH)D levels by 40, 76 and 206 nmol/L in those receiving the respective doses of 10, 20 and 50 mg/day. However, treatment with calcidiol did not increase 1,25(OH)D serum levels (Barger-Lux et al., 1998).

29. The ACNFP also reported findings from an unpublished randomised, controlled, double blind pharmacokinetic study. The response of serum 25(OH)D levels to calcidiol were compared to vitamin D₃ supplementation. The ACNFP reported findings from the Kunz et al., (2016) study that 20 µg/day could be safely administered for up to 6 months (Kunz et al., 2016). In addition to this being an unpublished study, no further information on the study was reported in the ACNFP safety assessment. However, EFSA, 2021 also cited this study, and reported findings of no changes in fasting 2-h

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

morning urine calcium/creatinine ratio over the 6-month study duration. Further findings from the study, as reported by EFSA, 2021, were that the 15 and 20 µg/day calcidiol dose groups had higher mean 24-hour urine calcium levels compared to the 20 µg/day vitamin D dose group. However, the urine calcium levels in both groups remained <300 mg/24 h which was labelled as “a range of no concern” by study authors (EFSA, 2021 citing Kunz et al., 2016).

30. In a randomised, double-blind study with 59 men and women aged ≥65 years, study authors concluded calcidiol to safely elevate serum 25(OH)D₃ level. Participants received either 5, 10 or 15 µg of calcidiol or 20 µg/vitamin D₃ and no cases of hypercalcemia occurred throughout the study duration. Adverse events were reported, however, none of them resulted in termination of the study and were deemed as unrelated to the treatment administered (Vaes et al., 2018).

31. In another study investigating the metabolic changes after calcidiol administration, no safety concerns were reported. Participants consisted of 18 healthy women aged 24-72 years who received calcidiol at doses of 500 µg/month over a 4-month period. However, it should be noted that this was not a safety study intentionally assessing adverse effects (Russo et al., 2011).

32. Many of the studies investigating the safety of calcidiol have been conducted in menopausal women. They have also been conducted in vitamin D deficient individuals (defined as serum 25(OH)D levels being <30 ng/mL by various study authors) due to calcidiol's higher potency than vitamin D and potential treatment for vitamin D deficiency (Quesada-Gomez, et al., 2023).

33. The safety and efficacy of calcidiol was studied in 45 postmenopausal women with vitamin D deficiency. Participants received doses of calcidiol at 0.266 mg/month (266 µg/month) over a 2-year duration. Study authors reported that mean 25(OH)D levels at month 24 of calcidiol administration was not significantly different to mean 25(OH)D levels at month 12. No significant changes in serum ionised calcium or creatinine were observed, and there were no significant changes in bone alkaline phosphatase serum levels

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

between 12 and 24 months. Study authors concluded that there were no safety concerns with long term administration of calcidiol as only one minor adverse event of mild dyspepsia (i.e. indigestion) was reported (Occhiuto et al., 2024).

34. In a double-blind randomised controlled trial, the safety and efficacy of calcidiol was compared with vitamin D₃ in 303 participants. Participants were vitamin D deficient postmenopausal women and received calcidiol in the form of capsules at a dose of 266 µg/month for 4 months. After this period participants were administered a placebo for 8 months followed by vitamin D₂ at 625 µg/month for 12 months. The highest serum 25(OH)D level reported was 60 ng/mL. No deaths were reported, only one participant had an adverse event that led to her withdrawal from the study and 8 participants reported at least one serious adverse event. However, study authors did not elucidate what these adverse events were and whether they were related to administration from calcidiol or vitamin D. Study authors concluded calcidiol to be safe in postmenopausal women as no serious adverse events were attributable to either calcidiol or vitamin D₃ (Pérez-Castrillón et al., 2020).

35. Calcidiol was demonstrated to be safe at daily doses of 20 µg/day, 40 µg/day or 125 µg/week for 3-months in 87 post-menopausal vitamin D deficient women aged 55 years and over. The levels of 25(OH)D remained within the study authors' safety window of 30 to 100 ng/mL after 14 days of treatment and no significant changes in markers for calcium and phosphate metabolism or bone turnover were reported. Furthermore, serum 25(OH)D levels were similar in both groups receiving 20 µg/day or 125 µg/week, serum levels were 49.3 and 46.4 ng/mL, respectively. However, 25(OH)D levels doubled in the group receiving 40 µg/day, with serum levels reaching 74.8 ng/mL. Ultimately, there was no difference in serum 25(OH)D levels between 30 and 90 days of treatment and study authors concluded that this indicated a plateau phase in short to medium term calcidiol administration (Minisola et al., 2017).

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

36. An earlier study administering calcidiol at 140 µg/week in a single dose resulted in serum 25(OH)D near 50 ng/mL (Jetter et al., 2014), which have been linked to non-classical adverse events and side effects of vitamin D supplementation such as falls or increased in bone turnover markers (Jetter et al., 2014, Rossini et al., 2012a, Rossini et al., 2012b).

37. In 20 healthy postmenopausal women aged 50-70 years receiving oral administrations of calcidiol at 20 µg/day over a 4-month period, no adverse effects were reported. As part of the study's compliance and safety regimen, adverse events were monitored, and serum calcium was measured. No adverse events were reported, and serum calcium levels were stable and did not exceed the upper end of the reference range (i.e. 2.19 - 2.60 nmol/L) throughout the 4 month follow up period. Study authors also reported "a safe, immediate sustained increase in 25(OH)D serum levels. However, this study was not a safety study set out to assess safety indications, but a study comparing the effectiveness of calcidiol and vitamin D₃ on serum 25(OH)D levels, lower extremity function, and innate immunity (Bischoff-Ferrari et al., 2012).

38. Graeff-Armas et al., 2020 also reported no safety concerns of calcidiol in a randomised, double-blind study that administered doses of 10, 15 and 20 µg/day for 6 months. The 91 participants of this study were healthy men and postmenopausal women aged 50 years and over.

39. It should be noted that this study was not a safety study but an efficacy study comparing the pharmacokinetics of calcidiol to vitamin D₃. However, safety and tolerability assessments were conducted that assessed serum calcium, creatine, 1,25(OH)₂D and parathyroid hormone. Complete metabolic panels, complete blood counts and adverse effects were reported. Study authors reported no significant changes to serum calcium, creatine, or 1,25 (OH)₂D from calcidiol administration. There was a statistically significant increase from baseline in 24-hour urinary calcium excretion at 20 µg/day in the calcidiol dose group compared to the vitamin D₃ group. Overall, safety laboratory parameters remained within normal reference ranges. None of the

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

adverse events reported were considered related to calcidiol or vitamin D₃ and did not result in participant withdrawal. Therefore, study authors concluded that “the intervention was well tolerated and safe” over the 6-month dosing period (Graeff-Armas et al., 2020).

40. Further studies reporting no safety concerns of calcidiol include a convenience study conducted by Navarro Valverde et al., (2016). Forty postmenopausal women (average age = 67 years) with osteoporosis received calcidiol orally for a period of 12 months at doses of 20 µg/day, 266 µg/week or 266 µg every other week. The participants of this study had pre-existing vitamin D deficiency with 25(OH)D levels at or below 37.5 ± 5 nmol/L. It should be noted that, the aim of this study was to compare the potency of vitamin D₃ and calcidiol, and not to assess safety. Also, the study authors did not describe any safety and compliance regimen undertaken, including the noting of adverse events and reported side effects.

41. In a phase I clinical trial assessing the safety and efficacy of calcidiol, it was concluded to be safe and effective in the young adult population. There were 101 participants aged 18-50 years with a mean age of 29.8 years. Participants received calcidiol over a 4-month period either monthly or every 2 weeks depending on their vitamin D deficiency. Participants with mild to moderate deficiency (defined as serum 25 (OH)D of 10 - <20 ng/mL by study authors) received calcidiol monthly. However, those with severe deficiency (defined as serum 25(OH)D of <10 ng/mL by study authors) received calcidiol every 2 weeks (Guerra López et al., 2024).

42. Safety results from the clinical trial showed only one participant developed 25(OH)D plasma levels >60 ng/mL whose levels returned to 10 ng/mL after termination of calcidiol treatment. Nine of the adverse events reported were considered to be potentially related to the study and were reported by 5% of participants receiving calcidiol monthly. These adverse events were of mild or moderate severity and included headache, non-clinically relevant increases in parathyroid hormone, nausea, abdominal discomfort, decreased appetite and diarrhoea (Guerra López et al., 2024).

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

43. No safety concerns of calcidiol administration were reported in a 16-week randomised controlled trial. There were 35 participants aged 18 years and over with vitamin D deficiency (defined as serum 25(OH)D of ≤ 20 ng/mL by study authors). Participants received either calcidiol at 60 μ g/day or vitamin D₃ at 20 μ g/day. Serum calcium and urinary calcium excretion were used as parameters of safety, and no significant changes from baseline levels were reported in these parameters. Furthermore, there were no reports of hypercalcemia, hypercalciuria or nephrolithiasis (kidney stones). Participants were also asked about adverse events, however, the occurrence and severity of any adverse events were unreported by the study authors (Shieh et al., 2017).

44. In a randomised study evaluating the efficacy and safety of calcidiol in 50 women with osteoporosis and osteopenia, calcidiol was reported to have long-term safety, by the study authors, at doses of 20 μ g/day and 30 μ g/day. Participants were aged 55-70 years and had 25(OH)D levels of 10-20 ng/mL and therefore vitamin D insufficient (defined by the study authors and the Institute of Medicine as 12-20 ng/ml) (Ross et al, 2011). Adverse events were monitored at baseline, 15, 30, 60, 90 and 180 days after the start of treatment. No adverse events were reported by the study authors. None of the participants presented hypercalcemia, and only one participant receiving calcidiol at 30 μ g/day presented borderline hypercalciuria (i.e. urinary calcium of 320 mg/24/hour). However, study authors stated that one of the key findings was “the confirmation about long-term safety of calcifiediol and the lack of toxic effects” (Gonnelli et al., 2021).

45. No adverse events from calcidiol were reported in a randomised, placebo-controlled, double-blind study comparing the effectiveness of calcidiol to vitamin D₃ in 56 participants. Participants were healthy white men and women and aged 50 years and over, and either consumed placebo, 20 μ g/day of vitamin D₃ or 7 or 20 μ g/day of calcidiol over a 10-week period. There were

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

no cases of hypercalcemia in the study, serum albumin-corrected calcium concentrations did not exceed 2.6 nmol/L (Cashman et al., 2012).

46. Other studies assessing the efficacy and safety of calcidiol include a longitudinal cohort study with 123 HIV-infected patients, 24% of which were female. Patients received monthly calcidiol doses of 16,000 IU/month (400 µg/month) and showed no signs of clinical toxicity. Serum 25(OH)D levels did not exceed >100 ng/ml, although patients had pre-existing vitamin D deficiency (defined as 25(OH)D of <10 – 29.9 ng/mL by study authors). Furthermore, there were no reported cases of hypercalcemia (defined as serum calcium of >10.5 ng/mL by study authors), gastrointestinal intolerance or headaches. Therefore, study authors concluded the monthly dose of calcidiol was safe in vitamin D deficient HIV-infected patients (Banon et al., 2015).

Preconception

47. There are currently no data available on the toxicological effect of calcidiol supplements during preconception. The [Statement on the potential effects of excess vitamin D intake during preconception, pregnancy and lactation had also reported “no information on the effect of excess vitamin D during preconception”](#) (COT, 2022).

Pregnancy

48. The data available on the toxicological effects of calcidiol supplements during pregnancy are limited. However, in a phase I clinical trial assessing the safety and efficacy of calcidiol in 101 participants aged 18-50 years with a mean age of 29.8 years. Participants received calcidiol over a 4-month period either monthly or every 2 weeks depending on their vitamin D deficiency. Participants with mild to moderate deficiency (defined as serum 25(OH)D of 10 - <20 ng/mL by study authors) received calcidiol monthly. However, those with severe deficiency (defined as serum 25(OH)D of <10 ng/mL) received calcidiol every 2 weeks. At the end of the treatment period there was one

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

reported case of pregnancy in the placebo group. However, due to the participant's vitamin D deficiency (serum 25(OH)D of <15 ng/mL) she was prescribed calcidiol by her obstetrician outside of the study, a dose of 0.255 mg/month for a duration of 54 days. Study authors confirmed the participant to have a normal delivery with no maternal or birth-related complications. Overall, study authors concluded calcidiol to be safe in doses trialled in this study (Guerra López et al., 2024).

49. Further information on the adverse effects of vitamin D during pregnancy have been addressed in the [Statement on the potential effects of excess vitamin D intake during preconception, pregnancy and lactation](#) (COT, 2022). These adverse effects include hypercalcaemia and hypercalciuria in pregnant women which may result in foetal morbidity. Neonatal hypercalcemia and or neonatal morbidity may also occur". Other possible adverse effects include high maternal blood pressure (COT, 2022).

Lactation

50. There are currently no data available on the toxicological effects of calcidiol during lactation. However, the limited evidence for the adverse effects of high vitamin D₂ and D₃ consumption during lactation have been addressed in the [Statement on the potential effects of excess vitamin D intake during preconception, pregnancy and lactation, where "possible hypercalciuria" was reported as the only adverse effect](#) (COT, 2022).

Health based guidance values

51. For vitamin D, EFSA established a tolerable upper intake level (UL) of 100 µg vitamin D/day, for adults (including pregnant and lactating women) and adolescents aged 11-17 years (EFSA, 2012). The UL covers all sources of dietary intake. In 2023, EFSA reconfirmed this 100 µg/day UL but expanded the definition to vitamin D equivalents (VDE), also for adults (including pregnant and lactating women) and adolescents aged 11-17 years. EFSA

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

proposed a factor of 2.5 for the conversion of calcidiol monohydrate into vitamin D3, for labelling purposes. The conversion factor accounts for its greater ability to increase serum 25(OH)D concentrations compared to vitamin D3, for doses up to 10 µg/day. (EFSA, 2023a).

52. The COT agreed with the UL for vitamin D and VDE (COT, 2014; COT, 2022). As discussed in the [Statement on the potential effects of excess vitamin D intake during preconception, pregnancy and lactation](#), the TUL does not cover individuals who may be more vulnerable to the adverse effects of vitamin D such as those with genetic predispositions (COT, 2022).

53. In EFSA's scientific and technical assistance to the evaluation of the safety of calcidiol monohydrate as a novel food, EFSA noted "that safety had been established up to 10 µg/day for these population groups (EFSA NDA Panel, 2021), which corresponds to 25 µg VDE/day considering a CF for calcidiol monohydrate into vitamin D3 of 2.5" (where CF is conversion factor) (EFSA, 2024).

54. EFSA stated the following reasons for their conclusions on the safety of calcidiol monohydrate under the proposed conditions use and use up to 10 µg/day for adolescence and adults (including pregnant and lactating women):

- I) "calcidiol monohydrate did not raise serum 25(OH)D concentrations above 107 nmol/L and did not increase the risk of hypercalcaemia, hypercalciuria or other adverse health effects at doses up to 10 µg/day in RCTs. The duration of the intervention ranged from 4 weeks to 12 months, depending on the study; and
- II) conservative, total combined vitamin D intake estimates from calcidiol (NF + background diet) and vitamin D (highest P95) from the background diet (up to 70.2 and 78.5 µg/day for adolescents and adults, respectively) were well below the UL for adolescents and adults, including pregnant and lactating women (100 µg/day)"

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

55. However, the ACNFP applied the 2.5 conversion factor to the TUL of 100 µg/day for vitamin D, and calculated calcidiol to have an adjusted upper intake of 40 µg/day for adults (ACNFP, 2024). The COT are in agreement with the ACNFP's upper intake level of 40 µg/day, which is greater than the level that EFSA established as safe (i.e. up to 10 µg/day). The COT were uncertain if the level EFSA established as safe was due to the proposed use of the regulated product assessed being only up to 10 µg/day or if it was derived by other means.

Exposure assessment

Exposure from ultraviolet (UV) B radiation

56. As discussed in the 2022 COT [Statement on the potential effects of excess vitamin D intake during preconception, pregnancy and lactation](#) “there are many factors affecting vitamin D formation such as season, time of day, amount of skin exposed, skin pigmentation and use of SPF sunscreen and this is reflected in the NHS Consensus Vitamin D position that states “there is still a lot of uncertainty around...how much sunlight different people need to achieve a given level of vitamin D” (NHS, 2010). Further information on serum 25(OH)D levels in multiple ethnicities with different exposure durations to UV radiation in different seasons has been discussed in the Statement on the potential effects of excess vitamin D intake during preconception, pregnancy and lactation.

57. Considering the above information, in 2022 the COT decided not to include exposure from UVB radiation in exposure assessment calculations. This was because “prolonged sunlight exposure does not lead to excess production of cutaneous vitamin D because endogenously produced pre-vitamin D₃ and vitamin D₃ are photolyzed to inert compounds” and that “even with prolonged irradiation in sunlight the amount of pre-vitamin D formed is limited to 12-15% of the original 7-DHC (MacLaughlin et al., 1982; Webb et al., 1988)” (SACN citing Hollick et al., 1980; MacLaughlin et al., 1982; Webb et al., 1988). ”.

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Occurrence of calcidiol in food

58. Calcidiol, may be present in some foods of animal origin such as milk, butter, eggs, fish, meat and offal in the form of 25-hydroxycholecalciferol (25(OH)D₃) or 25-hydroxyergocalciferol (25(OH)D₂). Calcidiol in the form 25-hydroxyergocalciferol has been reported in whole milk, butter and in some meat and offal (Ovesen et al., 2003; Jakobsen and Saxholt, 2009).

59. Occurrence of calcidiol in 11 food sources was reported in EFSA's 2021 paper '**Safety of calcidiol monohydrate produced by chemicals synthesis as a novel food pursuant to Regulation (EU)2015/2283**'. These levels have been summarised and can be found in Table 1.

Table 1. Foods containing calcidiol (Adapted from page 11 of [EFSA, 2021](#)).

Food	Form of calcidiol	Concentration (µg /kg)
Semi-skimmed milk	25-hydroxycholecalciferol	0.042
Whole milk	25-hydroxyergocalciferol	0.031
Butter	25-hydroxycholecalciferol,	0.96
Butter	25-hydroxyergocalciferol	0.58
Egg yolks	25-hydroxycholecalciferol	5 – 12
Salmon flesh	25-hydroxycholecalciferol	1.1
Raw trout	25-hydroxycholecalciferol	2.2
Pork cuts	25-hydroxycholecalciferol	0.7 – 1.4
Pork rind	25-hydroxycholecalciferol	3.4
Pork liver	25-hydroxycholecalciferol	4.8
Cow Kidney	25-hydroxycholecalciferol	5.1 – 9.8
Beef Liver	25-hydroxyergocalciferol	1.7

Food consumption

60. The following exposure assessments for calcidiol in food are based on consumption data from the National Diet and Nutrition Survey (NDNS) (Bates

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

et al., 2014, 2016, 2020; Roberts et al., 2018); however, it is important to note that the NDNS does not provide data for pregnant or lactating women.

Therefore, data presented below are based on women of childbearing age (16-49 years) and consumption data may not be entirely representative of the maternal diet, specifically in liver food groups due to National Health Service (NHS) recommendations that pregnant women should not consume liver or liver products (NHS, 2024). Evidence suggests that some foods and nutrients may be under-reported to a greater extent than others, and some may be overreported, but there is no information available on the level to which different foods are misreported in the NDNS in this group.

61. Consumption data were generated for all 11 food groups in Table 1 including both whole foods and recipes; these data can be found in Annex A. Table A1 provides acute consumption data and Table A2 provides chronic consumption data. Both tables summarise the mean and 97.5th percentile consumption per food group, for women of childbearing age.

Milk

62. A search within the recipes database of the NDNS (Bates et al., 2014, 2016, 2020; Roberts et al., 2018) was conducted to retrieve both semi-skimmed milk, whole milk, and recipes containing milk which had been recorded in the survey. Other types of milk were excluded as this search was conducted based on the food groups described in Table 1.

Butter

63. Calcidiol has been detected in butter as both 25-hydroxycholecalciferol and 25-hydroxyergocalciferol (EFSA, 2021). Consumption data were retrieved for butter and recipes containing butter.

Egg Yolk

64. Both whole egg and yolk only consumption was included from the NDNS database to ensure that all egg yolk consumers were included. Foods

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

containing egg white only were excluded from the assessment. The egg yolk makes up approximately 29.3% of the edible portion of a medium egg, and 28.7% of a large egg. The NDNS database does not specify the use of large or medium eggs therefore the figure was rounded to 29% (DH, 2012) and applied to whole egg foods to give estimates for consumption specifically of egg yolks.

Salmon

65. Foods containing salmon in the NDNS database do not specify with or without skin, however the assumption has been made that recipes represent salmon flesh.

Trout

66. Due to a low number of consumers of trout in the NDNS database, an 'all fish' food group was used as proxy based on the assumption that trout is eaten in similar quantities to other types of fish such as cod and haddock.

67. It is important to note that whilst levels of Calcidiol were detected in raw trout, both canned and cooked fish and fish recipes were used within this exposure assessment as raw trout data were not available within the NDNS.

Pork

68. Calcidiol is present in in pork cuts, pork rind, and pork liver as 25-hydroxycholecalciferol. The NDNS database was used to retrieve recipes containing varying forms of pork meat including pork belly, pork loin, sausages and bacon. Within the database, pork crackling was used to represent consumption of pork rind.

Beef kidney

69. Due to a low number of consumers of beef kidney in the NDNS database, an 'all kidney' food group was used as proxy based on the

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

assumption that kidney from animals such as lamb and pork would be consumed similarly.

Beef Liver

70. For women of childbearing age, within the NDNS database there are no consumers of beef liver, therefore an 'all liver' food group was used as proxy based on the assumption that liver from animals such as chicken and lamb would be consumed similarly.

Exposure estimates from food

71. An exposure assessment was conducted using food groups and occurrence levels presented in Table 1 only. A summary of exposure estimates for each food at its corresponding occurrence level of calcdiol can be found in Table 2 and 3. Table 2 provides acute exposure estimates to calcdiol from food, and Table 3 provides chronic exposure estimates, for women of childbearing age. In these tables, acute and chronic exposures are presented for both mean and 97.5th percentile groups on a per person and per kilogram bodyweight basis.

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Table 2: Estimated acute exposure to Calcidiol from food for women of childbearing age (16-49 years).

Food Groups	Type of Calcidiol	Level(s) detected (µg/kg)	Number of consumers	Mean (µg/person/day)*	P97.5 (µg/person/day)*	Mean (µg/kg bw/day)*	P97.5 (µg/kg bw/day)*
Semi-skimmed milk	25-hydroxycholecalciferol	0.042	2083	0.0085	0.026	0.00013	0.00041
Whole milk	25-hydroxyergocalciferol	0.031	1333	0.0041	0.017	0.000063	0.00026
Butter	25-hydroxycholecalciferol	0.96	1736	0.015	0.049	0.00023	0.00074
Butter	25-hydroxyergocalciferol	0.58	1736	0.0092	0.029	0.00014	0.00045
Egg yolk	25-hydroxycholecalciferol	5.0 - 12.0	2128	0.17- 0.41	0.46 -1.1	0.0025 - 0.0061	0.0072 - 0.017

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Salmon	25-hydroxycholecalciferol	1.1	375	0.087	0.22	0.0013	0.0036
Trout	25-hydroxycholecalciferol	2.2	168	0.17	0.52	0.0026	0.0082
Pork cuts	25-hydroxycholecalciferol	0.7 - 1.4	1406	0.049 - 0.099	0.15 - 0.3	0.00072 - 0.0014	0.0021 - 0.0044
Pork rind	25-hydroxycholecalciferol	3.4	69	0.053	0.21	0.00079	0.003
Pork liver	25-hydroxycholecalciferol	4.8	68	0.096	0.26	0.0013	0.0034
Cow Kidney	25-hydroxycholecalciferol	5.1 - 9.8	17**	0.077 - 0.15	0.14 - 0.27	0.0011 - 0.0021	0.0022 - 0.0042

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Beef Liver	25-hydroxyergocalciferol	1.7	96	0.063	0.21	0.00093	0.0036
------------	--------------------------	-----	----	-------	------	---------	--------

*Rounded to 2 s.f.

** Consumption or exposure estimates made with a small number of consumers may not be accurate. Where the number of consumers is less than 60, this should be treated with caution and may not be representative for a large number of consumers.

Table 3: Estimated chronic exposure to Calcidiol from food for women of childbearing age (16-49 years).

Food Groups	Type of Calcidiol	Level(s) detected (µg/kg)	Number of consumers	Mean (ug/person/day)*	P97.5 (ug/person/day)*	Mean (ug/kg bw/day)*	P97.5 (ug/kg bw/day)*
Semi-skimmed milk	25-hydroxycholecalciferol	0.042	2083	0.0048	0.017	0.000071	0.00024
Whole milk	25-hydroxyergocalciferol	0.031	1333	0.002	0.01	0.000031	0.00016
Butter	25-hydroxycholecalciferol	0.96	1736	0.0066	0.024	0.0001	0.00038

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Butter	25-hydroxyergocalciferol	0.58	1736	0.004	0.014	0.00006	0.00023
Egg yolks	25-hydroxycholecalciferol	5.0 - 12.0	2128	0.066 - 0.16	0.2 - 0.47	0.00098 - 0.0024	0.0032-0.0076
Salmon	25-hydroxycholecalciferol	1.1	375	0.025	0.059	0.00037	0.00098
Trout	25-hydroxycholecalciferol	2.2	168	0.047	0.16	0.0007	0.0022
Pork cuts	25-hydroxycholecalciferol	0.7 - 1.4	1406	0.016 - 0.033	0.057 - 0.11	0.00024 - 0.00048	0.00089 - 0.0018
Pork rind	25-hydroxycholecalciferol	3.4	69	0.015	0.053	0.00022	0.00079
Pork liver	25-hydroxycholecalciferol	4.8	68	0.028	0.09	0.0004	0.0013
Cow Kidney	25-hydroxycholecalciferol	5.1 - 9.8	17**	0.02 - 0.038	0.038 - 0.073	0.00027 - 0.00052	0.00055 - 0.001
Beef Liver	25-hydroxyergocalciferol	1.7	96	0.017	0.06	0.00026	0.00092

*Rounded to 2 s.f.

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

** Consumption or exposure estimates made with a small number of consumers may not be accurate. Where the number of consumers is less than 60, this should be treated with caution and may not be representative for a large number of consumers.

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Milk

72. Acute exposure estimates derived for 25-hydroxycholecalciferol in semi-skimmed milk at a concentration of 0.042 µg/kg are 0.0085 µg/day and 0.026 µg/day mean and 97.5th percentile values, respectively. Chronic exposure estimates are 0.0048 µg/day and 0.017 µg/day mean and 97.5th percentile values, respectively.

73. Acute exposure estimates derived for 25-hydroxyergocalciferol in whole milk at a concentration of 0.031 µg/kg are 0.0041 µg/day and 0.017 µg/day mean and 97.5th percentile values, respectively. Chronic exposure estimates are 0.002 µg/day and 0.01 µg/day mean and 97.5th percentile values respectively.

Butter

74. Calcidiol in butter was detected as 25-hydroxyergocalciferol at a concentration of 0.58 µg/kg and as 25-hydroxycholecalciferol at a concentration of 0.96 µg/kg and.

75. At a concentration of 0.58 µg/kg acute exposures were 0.0092 µg/day and 0.029 µg/day mean and 97.5th percentile values, respectively. At a concentration of 0.96 µg/kg, acute exposure estimates are 0.015 µg/day and 0.049 µg/day mean and 97.5th percentile values, respectively.

76. Chronic exposure estimates at a concentration of 0.58 µg/kg are 0.004 µg/day and 0.014 µg/day mean and 97.5th percentile values, respectively. At a concentration of 0.96 µg/kg, exposure estimates are 0.0066 µg/day and 0.024 µg/day mean and 97.5th percentile values, respectively.

Egg yolk

77. In egg yolk, 25-hydroxycholecalciferol was detected at a range of 5.0 to 12 µg/kg. Acute exposure estimates range from 0.17 to 0.41 µg/day and 0.46 to 1.1 µg/day mean and 97.5th percentile values, respectively. Chronic

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

exposure estimates range from 0.066 to 0.16 µg/day and 0.2 to 0.47 µg/day mean and 97.5th percentile values, respectively. The highest exposure to calcidiol from food was noted from egg yolks.

Salmon

78. Acute exposure estimates to 25-hydroxycholecalciferol in salmon at a level of 1.1 µg/kg are 0.087 µg/day and 0.22 µg/day mean and 97.5th percentile values, respectively. Chronic exposure estimates are 0.025 µg/day and 0.059 µg/day mean and 97.5th percentile values, respectively.

Pork

79. 25-hydroxycholecalciferol was detected at a range of 0.7 to 1.4 µg/kg in pork cuts, 3.4 µg/kg in rind (crackling), and 4.8 µg/kg in pork liver.

80. Acute mean exposures range from 0.049 to 0.099 µg/day in pork cuts, 0.053 µg/day in rind (crackling), and 0.096 µg/day in pork liver. Acute exposure estimates at the 97.5th percentile range from 0.15 to 0.3 µg/day in pork cuts, 0.21 µg/day in rind (crackling), and 0.26 µg/day in pork liver.

81. Chronic mean exposures range from 0.016 to 0.033 µg/day in pork cuts, 0.015 µg/day in rind (crackling), and 0.028 µg/day in pork liver. Chronic exposure estimates at the 97.5th percentile range from 0.057 to 0.11 µg/day in pork cuts, 0.053 µg/day in rind (crackling), and 0.09 µg/day in pork liver.

Beef

82. 25-hydroxycholecalciferol was detected in beef kidney at a range of 5.1 to 9.8 µg/kg, whilst 25-hydroxyergocalciferol was detected at a level of 1.7 µg/kg in beef liver.

83. Acute mean exposures range from 0.077 to 0.15 µg/day in beef kidney, and 0.063 µg/day in beef liver. Acute exposure estimates at the 97.5th

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

percentile range from 0.14 to 0.27 µg/day in beef kidney, and 0.21 µg/day in beef liver.

84. Chronic mean exposures range from 0.02 to 0.038 µg/day in beef kidney, and 0.017 µg/day in beef liver. Chronic exposure estimates at the 97.5th percentile range from 0.038 to 0.073 µg/day in beef kidney, and 0.06 µg/day in beef liver.

Total exposure estimates from food sources

85. Estimated total exposures to calcidiol from 11 food sources (Table 1), in women aged 16-49 years, are presented in Tables 3 and 4 below. Due to a range of occurrence values for some food groups, these data have been presented as minimum and maximum exposure estimates. Exposure data from food sources containing calcidiol will be compared to the ACNFP TUL of 40 µg/day and the level EFSA established as safe (i.e., up to 10 µg/day).

Table 3. Estimated total acute exposure to calcidiol from food sources (excluding supplements) in women aged 16-49 years.

Total calcidiol exposure** (food sources)	Mean (µg/person/day) *	P97.5 (µg/person /day) *	Mean (µg/kg bw/day)*	P97.5 (µg/kg bw/day)*
Minimum	0.19	0.5	0.0028	0.008
Maximum	0.4	1.1	0.006	0.017

*Rounded to 2 s.f.

** Determined from a distribution of consumption of any combination of categories, rather than by summation of the respective individual mean / 97.5th percentile consumption value for each of the 11 food categories.

86. Women of childbearing age are estimated to have minimum acute calcidiol exposures of 0.19 and 0.5 µg/day for mean and 97.5th percentile

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

consumption, respectively. Maximum acute exposures are 0.4 and 1.1 µg/day for mean and 97.5th percentile consumption, respectively.

Table 4. Estimated total chronic exposure to calcidiol from food sources (excluding supplements) in women aged 16-49 years.

Total calcidiol exposure** (food sources)	Mean (µg/person/day)*	P97.5 (µg/person/day)*	Mean (µg/kg bw/day)*	P97.5 (µg/kg bw/day)*
Minimum	0.082	0.24	0.0012	0.0038
Maximum	0.17	0.52	0.0025	0.0081

* Rounded to 2 s.f.

**Determined from a distribution of consumption of any combination of categories, rather than by summation of the respective individual mean / 97.5th percentile consumption value for each of the 11 food categories.

87. Women of childbearing age are estimated to have minimum chronic exposures of calcidiol at 0.082 and 0.24 µg/day mean and 97.5th percentile values, respectively. Maximum exposures are 0.17 and 0.52 µg/day mean and 97.5th percentile values, respectively.

Exposure estimates from supplements

88. Calcidiol is currently available in supplemental form and may be used in future food fortification (Guo et al., 2017). Calcidiol is present in supplements in the form of calcifediol or 25(OH)D (Biondi et al., 2017).

89. Supplements aimed at adults were identified using online sources which supplied calcidiol in doses ranging from 10 to 20 µg/day. No supplements containing calcidiol were identified that were specifically aimed at pregnant and breast-feeding women.

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

90. Estimate calcidiol exposures from calcidiol-containing supplements are presented in Table 5. These exposure estimates assume that a 70.3 kg female between the ages of 16 to 49 consumes the supplement at the recommended dose for adults. The bodyweight of 70.3 kg was determined as the mean bodyweight of all females of childbearing age (16 to 49 years) within years 1-11 of the NDNS database.

91. The limited number of calcidiol-containing supplements available on the market are presented in Table 5, some of which are not available in the UK, but are able to be ordered online from international stores.

Table 5. Calcidiol exposure estimates for women of childbearing age consuming calcidiol-containing supplements*

Supplement	Calcidiol concentration per serving (µg)	Serving size (tablets/day)	Calcidiol exposure (µg/kg bw/day)**
VitamoreD - Vitamin D3 as Calcifediol	10	1	0.14
D.velop Tablets Adult	20	2	0.28
D.velop Gummies Adult	10	2	0.14
Bioclinic Naturals Opti Active D	10	1	0.14
Vitamin D DPrev Active	10	1	0.14

* based on a bodyweight of 70.3kg.

** Rounded to 2 s.f.

92. The supplements listed in Table 5 are generally aimed at adults although it should be noted that pregnant women may consume these

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

supplements as many individuals are unaware of their pregnancy at the time and may consume calcidiol-containing supplements that are of higher potency than vitamin D₂ and D₃ supplements.

93. The estimated calcidiol exposures from calcidiol-containing supplements range from 10 to 20 µg/day, which is equivalent to 0.14 to 0.28 µg/kg bw/day.

Total exposure estimates from food and supplements combined

94. Total exposure estimates to calcidiol from food and supplement sources combined in women aged 16-49 years are presented in Tables 6 and 7 below. For acute exposure estimates, total exposure from food sources (Table 2) was summed with exposure data from dietary supplements (Table 5). For chronic exposure estimates, total exposure from food sources (Table 4) was summed with exposure data from dietary supplements (Table 5).

95. To calculate the minimum total exposures in Tables 6 and 7, the lowest supplement exposure (10 µg/person/day or 0.14 µg/kg bw/day) was summed with the minimum exposures from food (Tables 4 and 5) for both mean and 97.5th percentile consumption. To calculate the maximum total exposures as seen in Tables 6 and 7, the highest supplement exposures from Table 5 (20 µg/person/day or 0.28 µg/kg bw/day) were summed with the maximum exposures from food (Tables 3 and 4) for both mean and 97.5th percentile consumption.

Table 6. Estimated total acute calcidiol exposure from food sources combined with supplements in women aged 16-49 years.

Total calcidiol exposure (food + supplements)	Mean (ug/person/day)*	P97.5 (ug/person/day)*	Mean (µg/kg bw/day)*	P97.5 (µg/kg bw/day)*

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Minimum	10	11	0.14	0.15
Maximum	20	21	0.29	0.3

* Rounded to 2 s.f.

96. Minimum total acute calcidiol exposures from all dietary sources including supplements, for women aged 16-49 years, are 10 µg/day and 11 µg/day for mean and 97.5th percentile consumption, respectively. Maximum total acute exposures from all dietary sources including supplements are 20 µg/day and 21 µg/day mean and 97.5th percentile, respectively.

Table 7. Estimated total chronic calcidiol exposure from food sources combined with supplements in women aged 16-49 years.

Total calcidiol exposure (food + supplements)	Mean (ug/person/day)*	P97.5 (ug/person/day)*	Mean (µg/kg bw/day)*	P97.5 (µg/kg bw/day)*
Minimum	10	10	0.14	0.14
Maximum	20	21	0.28	0.29

* Rounded to 2 s.f.

97. Minimum total chronic calcidiol exposure from all dietary sources including supplements amongst women aged 16-49 years is 10 µg/day for both mean and 97.5th percentile groups. Maximum total chronic exposures from all food sources are 20 µg/day and 21 µg/day mean and 97.5th percentile values, respectively. Exposure to calcidiol from dietary sources are minor relative to exposure from supplements.

Risk characterisation

98. All calcidiol-containing supplements available on the market did not exceed the ACNFP TUL of 40 µg/day. All supplements currently available on the market with the exception of “D.velop Tablets Adult” were at the level

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

EFSA established as safe (i.e., up to 10 µg/day). The “Develop Tablets Adult” exceeded the level EFSA established as safe (i.e., up to 10 µg/day) by 2-fold.

99. The highest estimated exposures of calcidiol from food sources only, was 1.1 µg/day, which is significantly below the ACNFP TUL of 40 µg/day and the level EFSA established as safe (i.e., up to 10 µg/day). For food and calcidiol supplements combined, maximum mean exposures of calcidiol exceeded the level EFSA established as safe (i.e., up to 10 µg/day) by 2-fold. The minimum 97.5th percentile intake marginally exceeded the level EFSA established as safe (i.e., up to 10 µg/day), whereas the maximum 97.5th percentile intake exceeded the level EFSA established as safe (i.e., up to 10 µg/day) by 2.1-fold. However, all mean and 97.5th percentile chronic intakes of calcidiol from food and supplements combined were below the ACNFP TUL of 40 µg/day. Individuals with a loss of function mutation in enzyme CYP24A1 are more likely to have higher circulating levels of calcidiol in their blood as this enzyme is responsible for the breakdown of calcidiol and 1,25(OH)₂D (Jones et al., 2012) and are therefore more prone to the effects of excessive calcidiol exposure.

100. It should also be noted that supplements are likely to be the greatest contributor to calcidiol intake in women of childbearing age, whereas calcidiol intake from the food sources alone is low. Furthermore, not all women of child-bearing age consume supplements. Results from the most recent NDNS (years 9-11) report have shown that between 2016-2019 20% of female respondents aged 19-64 years consume vitamin D supplements (Bates et al, 2020).

101. The main uncertainties in this assessment were that the NDNS does not specifically include data for pregnant and lactating women, so women of child-bearing age (i.e. 16-49 years) were used as a proxy for these consumer groups, and there is little information on how their diets might differ.

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

102. Further uncertainties include the limited data available on calcidiol's safety in pregnant women. Most of the human studies and case reports discussed include post-menopausal women and individuals with vitamin D deficiency and are therefore not specific to populations of women of childbearing age. Although in their 2024 opinion EFSA acknowledged that bioavailability and safety data were lacking for pregnancy and lactating women but considered "the data available for adults were sufficient to cover these population groups". (EFSA, 2024).

103. Other uncertainties may include background exposure from UVB radiation. Although, exposure to UVB radiation is unlikely to result in adverse serum 25(OH) levels, even when consuming dietary intakes of calcidiol, due to an inbuilt mechanism in the skin. SACN, 2016 stated that "prolonged sunlight exposure does not lead to excess production of cutaneous vitamin D". This is "because endogenously produced pre-vitamin D3 and vitamin D3 are photolyzed to inert compounds" (SACN, 2018), thus preventing conversion into its primary metabolite; 25(OH)D, (i.e. calcidiol) (ACNFP, 2024; Perez-Lopez et al., 2015). SACN also stated that "Vitamin D3 is produced endogenously from 7-dehydrocholesterol (7-DHC) in the skin of humans and animals by the action of sunlight containing UVB radiation (wavelength 280-315 nm) or by artificial UVB light". The 7-DHC in the epidermis is converted to pre-vitamin D3, which reaches a maximum concentration in the skin within a few hours (Holick et al., 1980)" (SACN, 2018).

Conclusions

104. Exposure in, pregnant and lactating women, and women attempting conception who do not take calcidiol supplements, and whose only exposure to calcidiol is from food sources, does not exceed the ACNFP TUL of 40 µg/day and the level EFSA established as safe (i.e., up to 10 µg/day).

105. When considering exposure estimates from all sources (food and supplements combined), for women of childbearing age, all intakes were below the ACNFP TUL of 40 µg/day. Only the minimum and maximum 97.5th

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

percentile intakes exceed the level EFSA established as safe (i.e., up to 10 µg/day) up to 1.1 and 2.1-fold respectively. However, the COT noted that supplements are likely the greatest contributor to calcidiol exposure in these population groups. Furthermore, not all women of child-bearing age take supplements, it has been estimated that 20% of females aged 19-64 years take vitamin D supplements.

106. Exposure from calcidiol supplements and calcidiol from food sources in healthy pregnant and lactating women are unlikely to result in significant exceedances of the ACNFP TUL and the level EFSA established as safe . However, sensitive individuals with loss or function mutations would be more susceptible to the effects of calcidiol.

Questions on which the views of the Committee are sought

1. Does the Committee have any comments on the potential risks of calcidiol supplements on maternal or fetal health?
2. Is the Committee content with using a HBGV of 10 or 40 µg/day for risk characterisation?
3. Does the Committee have any other comments on the contents of this review?

Secretariat

May 2025

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

List of Abbreviations and Technical terms

25(OH)D	25-hydroxyvitamin D
ACNFP	Advisory Committee on Novel Foods and Processes
COT	Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment
EC	European Commission
EFSA	The European Food Safety Authority
FSA	Food Standards Agency
FSS	Food Standards Scotland
HBGV	Health Based Guidance Value
IU	International Units
LOAEL	Lowest Observed Adverse Effect Level
mg	milligrams
NDA	Panel on Nutrition, Novel Foods and Food Allergens (NDA)
NDNS	National Diet and Nutrition Survey
ng	Nanograms
nmol	Nanomole
NOAEL	No Observed Adverse Effect Level
OECD	The Organization for Economic Cooperation and Development
kg	Kilograms
RCT	Randomised Clinical Trial
SACN	Scientific Advisory Committee on Nutrition
TUL	Tolerable Upper Intake Level
UL	Upper level
VDE	Vitamin D equivalents

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

References

Advisory Committee on Novel Foods and Processes (ACNFP). (2024). ACNFP Safety Assessment: Calciol (25-hydroxycholecalciferol monohydrate) as a novel food for use in food Supplements [ACNFP Safety Assessment: Calciol \(25-hydroxycholecalciferol monohydrate\) | Advisory Committee on Novel Foods and Processes](#)

Bañón, S., Rosillo, M., Gómez, A., Pérez-Elias, M.J., Moreno, S. and Casado, J.L. (2015). Effect of a monthly dose of calciol in improving vitamin D deficiency and secondary hyperparathyroidism in HIV-infected patients. Endocrine, 49, pp.528-537. [Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults - ScienceDirect](#)

Barger-Lux MJ, Heaney RP, Dowell S, Chen TC, Holick MF. (1998). Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. Osteoporos Int 8(3):222-230. [Vitamin D and its Major Metabolites: Serum Levels after Graded Oral Dosing in Healthy Men | Osteoporosis International](#)

Bates B, Lennox A, Prentice A, Bates C, Page P, Nicholson S, Swan G (2014). National Diet and Nutrition Survey Results from Years 1, 2, 3 and 4 (combined) of the Rolling Programme (2008/2009 – 2011/2012): [Main heading](#)

Bates, B.; Cox, L.; Nicholson, S.; Page, P.; Prentice, A.; Steer, T.; Swan, G. (2016) National Diet and Nutrition Survey Results from Years 5 and 6 (combined) of the Rolling Programme (2012/2013 – 2013/2014). [NDNS: results from years 9 to 11 \(2016 to 2017 and 2018 to 2019\) - GOV.UK](#)

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Bates, B.; Collins, D.; Jones, K.; Page, P.; Roberts, C.; Steer, T.; Swan, G. (2020) National Diet and Nutrition Survey Results from years 9, 10 and 11 (combined) of the Rolling Programme (2016/2017 to 2018/2019). [Link here](#)

Biondi, P., Pepe, J., Biamonte, F., Occhiuto, M., Parisi, M., Demofonti, C., Baffa, V., Minisola, S. and Cipriani, C. (2017). Oral calcidiol is a good form of vitamin D supplementation. *Clinical Cases in Mineral and Bone Metabolism*, 14(2), p.207.

Bischoff-Ferrari, H.A. and Dawson-Hughes, B. (2012). Stöcklin E, Sidelnikov E, Willett WC, Orav EJ et al. Oral supplementation with 25 (OH) D3 versus vitamin D3: effects on 25 (OH) D levels, lower extremity function, blood pressure and markers of innate immunity. **J Bone Miner Res**, 27, pp.160-169. [Oral supplementation with 25\(OH\)D3 versus vitamin D3: effects on 25\(OH\)D levels, lower extremity function, blood pressure, and markers of innate immunity - PubMed](#)

Brandi, M.L. and Minisola, S. (2013). Calcidiol [25 (OH) D3]: from diagnostic marker to therapeutical agent. *Current medical research and opinion*, 29(11). pp.1565-1572.

Cashman, K.D., Seamans, K.M., Lucey, A.J., Stöcklin, E., Weber, P., Kiely, M. and Hill, T.R. (2012). Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults. *The American journal of clinical nutrition*, 95(6), pp.1350-1356. [Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults - PubMed](#)

Clausen I, Jakobsen J, Leth T and Ovesen L. (2003). Vitamin D3 and 25-hydroxyvitamin D3 in raw and cooked porkcuts. *Journal of Food Composition and Analysis*, 16, 575–585. [Vitamin D3 and 25-hydroxyvitamin D3 in raw and cooked pork cuts - ScienceDirect](#)

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Committee on toxicity of chemicals in food, consumer products and the environment (COT). (2014). Statement on adverse effects of high levels of vitamin D. [\[ARCHIVED CONTENT\] UK Government Web Archive - The National Archives](#)

Committee on toxicity of chemicals in food, consumer products and the environment (COT) (2022). Statement on the potential effects of excess vitamin D intake during preconception, pregnancy and lactation [TOX-2021-45 Second draft statement Vitamin D V05](#)

Department of health (DH). (2012). Nutrient analysis of eggs Sampling Report. [Nutrient analysis of eggs - Sampling report \(publishing.service.gov.uk\)](#) Nutrient analysis of eggs - Sampling report (publishing.service.gov.uk).

Donati, S., Marini, F., Giusti, F., Palmini, G., Aurilia, C., Falsetti, I., Iantomasi, T. and Brandi, M.L., (2023). Calcifediol: why, when, how much? **Pharmaceuticals**, **16**(5), p.637. [Calcifediol: Why, When, How Much? - PMC](#)

EFSA (2021). Safety of calcidiol monohydrate produced by chemical synthesis as a novel food pursuant to Regulation (EU) 2015/2283. **EFSA Journal**, **19**(7), p.e06660.

EFSA (2023a). Scientific opinion on the tolerable upper intake level for vitamin D, including the derivation of a conversion factor for calcidiol monohydrate. **EFSA Journal**, **21**(8), p.e08145.

EFSA (2024). Scientific and technical assistance to the evaluation of the safety of calcidiol monohydrate as a novel food. **EFSA Journal**, **22**(1), p.e8520.food [Scientific and technical assistance to the evaluation of the safety of calcidiol monohydrate as a novel food](#)

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Gázquez, A., Sánchez-Campillo, M., Barranco, A., Rueda, R., Chan, J.P., Kuchan, M.J. and Larqué, E. (2022). Calcifediol during pregnancy improves maternal and fetal availability of vitamin D compared to vitamin D3 in rats and modifies fetal metabolism. *Frontiers in Nutrition*, 9, p.871632.

Gonnelli, S., Tomai Pitinca, M.D., Camarri, S., Lucani, B., Franci, B., Nuti, R. and Caffarelli, C., (2021). Pharmacokinetic profile and effect on bone markers and muscle strength of two daily dosage regimens of calcifediol in osteopenic/osteoporotic postmenopausal women. *Aging Clinical and Experimental Research*, pp.1-9. [Pharmacokinetic profile and effect on bone markers and muscle strength of two daily dosage regimens of calcifediol in osteopenic/osteoporotic postmenopausal women - PMC](#)

Graeff-Armas, L.A., Bendik, I., Kunz, I., Schoop, R., Hull, S. and Beck, M. (2020). Supplemental 25-hydroxycholecalciferol is more effective than cholecalciferol in raising serum 25-hydroxyvitamin D concentrations in older adults. *The Journal of nutrition*, **150**(1), pp.73-81. [Supplemental 25-Hydroxycholecalciferol Is More Effective than Cholecalciferol in Raising Serum 25-Hydroxyvitamin D Concentrations in Older Adults - ScienceDirect](#)

Guerra López, P., Urroz Elizalde, M., Vega-Gil, N., Sánchez Santiago, B., Zorrilla Martínez, I., Jiménez-Mercado, M., Jódar, E., Landeta Manzano, A., Campo Hoyos, C. and Frías Iniesta, J. (2024). Efficacy and Safety of Calcifediol in Young Adults with Vitamin D Deficiency: A Phase I, Multicentre, Clinical Trial—POSCAL Study. *Nutrients*, 16(2), p.306. [Efficacy and Safety of Calcifediol in Young Adults with Vitamin D Deficiency: A Phase I, Multicentre, Clinical Trial—POSCAL Study](#)

Guo, J., Lovegrove, J.A. and Givens, D.I. (2018). 25 (OH) D3-enriched or fortified foods are more efficient at tackling inadequate vitamin D status than vitamin D3. *Proceedings of the Nutrition Society*, 77(3), pp.282-291. [25\(OH\)D3-enriched or fortified foods are more efficient at tackling inadequate vitamin D status than vitamin D3 - PMC](#)

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Hard, G.C. (2014) Expert Review of Histological Changes In Rat Kidney from a 90- Day Toxicity Study with Orally Administered DSM047117. Prepared for: DSM Nutritional Products AG, Wurmisweg 576, CH-4303 Kaiseraugst, Switzerland. Submitted as an appendix to Thiel et al, 2014c. DSM proprietary unpublished study.

Hathcock, J.N., Shao, A., Vieth, R. and Heaney, R., 2007. Risk assessment for vitamin D. **The American journal of clinical nutrition**, **85**(1), pp.6-18.

[Risk assessment for vitamin D - ScienceDirect](#)

Heaney, R.P. (2008). Vitamin D: criteria for safety and efficacy. Nutrition reviews, 66(suppl_2), pp.S178-S181. [Vitamin D: criteria for safety and efficacy | Nutrition Reviews | Oxford Academic](#)

Henríquez, M,S and Gómez de Tejada Romero, M.J. (2020). Cholecalciferol or calcifediol in the management of vitamin D deficiency. **Nutrients**, **12**(6), p.1617. [Cholecalciferol or Calcifediol in the Management of Vitamin D Deficiency - PMC](#)

Institute Of Medicine (2011) Dietary Reference Intakes for Calcium and vitamin D. ISBN 978-0-309-16394-1. [Dietary Reference Intakes for Calcium and Vitamin D | The National Academies Press](#)

Jakobsen J and Saxholt E. (2009). Vitamin D metabolites in bovine milk and butter. Journal of Food Composition and Analysis, 22, 472–478. [Vitamin D metabolites in bovine milk and butter - ScienceDirect](#)

Jetter, A., Egli, A., Dawson-Hughes, B., Staehelin, H.B., Stoecklin, E., Goessl, R., Henschkowski, J. and Bischoff-Ferrari, H.A. (2014). Pharmacokinetics of oral vitamin D3 and calcifediol. Bone, 59, pp.14-19. [Pharmacokinetics of oral vitamin D3 and calcifediol - ScienceDirect](#)

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Jones, G., Prosser, D.E. and Kaufmann, M. (2012). 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. **Archives of biochemistry and biophysics**, **523**(1), pp.9-18.

Maghbooli, Z., Sahraian, M.A., Jamalimoghadamsiahkali, S., Asadi, A., Zarei, A., Zendehdel, A., Varzandi, T., Mohammadnabi, S., Alijani, N., Karimi, M. and Shirvani, A., (2021). Treatment with 25-hydroxyvitamin D3 (calcifediol) is associated with a reduction in the blood neutrophil-to-lymphocyte ratio marker of disease severity in hospitalized patients with COVID-19: a pilot multicenter, randomized, placebo-controlled, double-blinded clinical trial. *Endocrine Practice*, *27*(12), pp.1242-1251. [Treatment With 25-Hydroxyvitamin D3 \(Calcifediol\) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial - PMC](#)

Minisola, S., Cianferotti, L., Biondi, P., Cipriani, C., Fossi, C., Franceschelli, F., Giusti, F., Leoncini, G., Pepe, J., Bischoff-Ferrari, H.A. and Brandi, M.L., (2017). Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens. *Osteoporosis International*, *28*, pp.3239-3249. [Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens | Osteoporosis International](#)

Navarro-Valverde, C., Sosa-Henríquez, M., Alhambra-Expósito, M.R. and Quesada-Gómez, J.M. (2016). Vitamin D3 and calcidiol are not equipotent. *The Journal of Steroid Biochemistry and Molecular Biology*, *164*, pp.205-208. [Vitamin D3 and calcidiol are not equipotent - ScienceDirect](#)

NHS (2024). Meat in your diet. [Meat in your diet - NHS](#)

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Occhiuto, M., Pepe, J., Colangelo, L., Lucarelli, M., Angeloni, A., Nieddu, L., De Martino, V., Minisola, S. and Cipriani, C. (2024). Effect of 2 Years of Monthly Calcifediol Administration in Postmenopausal Women with Vitamin D Insufficiency. *Nutrients*, 16(11), p.1754. [Effect of 2 Years of Monthly Calcifediol Administration in Postmenopausal Women with Vitamin D Insufficiency](#)

Ovesen L, Brot C and Jakobsen J. (2003). Food contents and biological activity of 25-hydroxyvitamin D: a vitamin D metabolite to be reckoned with? *Annals of Nutrition and Metabolism*, 47, 107–113. [Food contents and biological activity of 25-hydroxyvitamin D: a vitamin D metabolite to be reckoned with? - PubMed](#)

Pereda, C.A. and Nishishinya, M.B. (2022). Optimal dosage of vitamin D supplementation in obese patients with low serum levels of 25-Hydroxyvitamin D. A systematic review. *Obesity Medicine*, 29, p.100381.

Pérez-Castrillón, J.L., Dueñas-Laita, A., Brandi, M.L., Jódar, E., del Pino-Montes, J., Quesada-Gómez, J.M., Cereto Castro, F., Gómez-Alonso, C., Gallego López, L., Olmos Martínez, J.M. and Alhambra Expósito, M.R., (2020). Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial. *Journal of Bone and Mineral Research*, 36(10), pp.1967-1978. [Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial | Journal of Bone and Mineral Research | Oxford Academic](#)

Quesada-Gomez, J.M. and Bouillon, R. (2023). Calcifediol cornerstone of the vitamin D endocrine system. *Nutrients*, 15(10), p.2290. [Calcifediol Cornerstone of the Vitamin D Endocrine System](#)

Remus T and Verspeek-Rip C. (2016). Evaluation of the mutagenic activity of DSM047117 in an in vitro mammalian cell gene mutation test with L5178Y mouse lymphoma cells (Study conducted at WIL Research Europe B.V., 5231

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

DD's Hertogenbosch, The Netherlands; WIL study number 511352). DSM Proprietary unpublished data.

Robbins, R.N., Serra, M., Ranjit, N., Hoelscher, D.M., Sweitzer, S.J. and Briley, M.E. (2022). Efficacy of various prescribed vitamin D supplementation regimens on 25-hydroxyvitamin D serum levels in long-term care. Public Health Nutrition, 25(1), pp.82-89. [Efficacy of various prescribed vitamin D supplementation regimens on 25-hydroxyvitamin D serum levels in long-term care | Public Health Nutrition | Cambridge Core](#)

Roberts, C.; Steer, T.; Maplethorpe, N.; Cox, L.; Meadows, S.; Page, P.; Nicholson, S.; Swan, G. (2018) National Diet and Nutrition Survey Results from Years 7 and 8 (combined) of the Rolling Programme (2014/2015 – 2015/2016) [National Diet and Nutrition Survey](#)

Ross, A.C., Manson, J.E., Abrams, S.A., Aloia, J.F., Brannon, P.M., Clinton, S.K., Durazo-Arvizu, R.A., Gallagher, J.C., Gallo, R.L., Jones, G. and Kovacs, C.S. (2011). The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. The Journal of Clinical Endocrinology & Metabolism, 96(1), pp.53-58. [2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic](#)

Rossini, M., Viapiana, O., Gatti, D., James, G., Girardello, S. and Adami, S., (2005). The long term correction of vitamin D deficiency: comparison between different treatments with vitamin D in clinical practice. Minerva medica, 96, pp.1-7. [Short-Term Effects on Bone Turnover Markers of a Single High Dose of Oral Vitamin D3 | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic](#)

Rossini, M., Adami, S., Viapiana, O., Fracassi, E., Idolazzi, L., Povino, M.R. and Gatti, D., (2012b). Dose-Dependent Short-Term Effects of Single High

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Doses of Oral Vitamin D 3 on Bone Turnover Markers. *Calcified Tissue International*, 91, pp.365-369. [Dose-Dependent Short-Term Effects of Single High Doses of Oral Vitamin D3 on Bone Turnover Markers | Calcified Tissue International](#)

Russo, S., Carlucci, L., Cipriani, C., Ragno, A., Piemonte, S., Fiacco, R.D., Pepe, J., Fassino, V., Arima, S., Romagnoli, E. and Minisola, S. (2011). Metabolic changes following 500 µg monthly administration of calcidiol: a study in normal females [Abstract]. *Calcified tissue international*, 89, pp.252-257. [Metabolic Changes Following 500 µg Monthly Administration of Calcidiol: A Study in Normal Females | Calcified Tissue International](#)

SACN. (2016). SACN vitamin D and health report. [SACN vitamin D and health report - GOV.UK](#)

Shieh, A., Ma, C., Chun, R.F., Witzel, S., Rafison, B., Contreras, H.T., Wittwer-Schegg, J., Swinkels, L., Huijs, T., Hewison, M. and Adams, J.S. (2017). Effects of cholecalciferol vs calcifediol on total and free 25-hydroxyvitamin D and parathyroid hormone. **The Journal of Clinical Endocrinology & Metabolism**, **102**(4), pp.1133-1140. [Effects of Cholecalciferol vs Calcifediol on Total and Free 25-Hydroxyvitamin D and Parathyroid Hormone | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic](#)

Stamp, T.C.B., Haddad, J.G. and Twigg, C.A. (1977). Comparison of oral 25-hydroxycholecalciferol, vitamin D, and ultraviolet light as determinants of circulating 25-hydroxyvitamin D. *The Lancet*, 309(8026). pp.1341-1343.

Thiel A, Scase K, Hofman P, Kohnlein M and Martland MF. (2007). 3-month oral toxicity with Rovimix D3-500 by dietary administration followed by a 4-week recovery period in Wistar rats. DSM proprietary unpublished data.

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Vaes, A.M., Tieland, M., de Regt, M.F., Wittwer, J., van Loon, L.J. and de Groot, L.C. (2018). Dose–response effects of supplementation with calcifediol on serum 25-hydroxyvitamin D status and its metabolites: a randomized controlled trial in older adults. *Clinical nutrition*, 37(3), pp.808-814.

Verbaan, IAJ and Remus T. (2016). DSM047117: Micronucleus test in bone marrow cells of the rat. DSM Proprietary unpublished data.

Vicchio, D., Yergey, A., O'Brien, K., Allen, L., Ray, R. and Holick, M. (1993). Quantification and kinetics of 25-hydroxyvitamin D3 by isotope dilution liquid chromatography/thermospray mass spectrometry. *Biological mass spectrometry*, 22(1), pp.53-58.

Vieth, R. (2020). Vitamin D supplementation: cholecalciferol, calcifediol, and calcitriol. *European Journal of Clinical Nutrition*. 74(11), pp.1493-1497.

Weber E and Schulz M. (2005). Chromosome Aberration Test in Human Lymphocytes in vitro with Calcifediol. DSM Proprietary unpublished data.

Wöhrle T and Sokolowski A. (2013). DSM047117: Salmonella typhimurium and Escherichia coli reverse mutation assay. (Study conducted at Harlan CCR; D64380 Rossdorf; Harlan CCR study Number 1533500). DSM Proprietary unpublished data.

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Search Terms

The references cited in this discussion paper are of publications found in Pubmed, Scopus and Springer, searched using Lit fetch. The publication retrieved were selected using the following search terms:

Calcidiol AND toxicity,
Calcidiol AND Pregnancy,
Calcidiol AND lactation,
Calcidiol AND conception,
Calcidiol AND birth defects,
Calcidiol AND vitamin D,
Calcidiol AND supplements,
Calcifediol AND safety,
25 (OH)D AND safety.

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

TOX/2025/21 Annex A

The data presented in the tables below are based on consumers of foods reported in the NDNS ((Bates et al., 2014, 2016; 2018, 2020).

Table A1: Estimated acute exposure of foods containing Calcidiol for women of childbearing age (16-49 years).

Food Groups	No. of consumers	Mean consumption (g/person/day) *	97.5 consumption (g/person/day) *	Mean Exposure (µg/kg bw/day) *	P97.5 exposure (µg/kg bw/day)*
Semi-skimmed milk	2083	200	620	3	9.7
Whole milk	1333	130	560	2	8.5
Butter	1736	16	51	0.24	0.77
Egg yolk	2128	34	93	0.5	1.4
Salmon	375	79	200	1.2	3.3
Trout	168	78	240	1.2	3.7
Pork cuts	1406	70	210	1	3.1
Pork rind	69	16	62	0.23	0.89
Pork liver	68	20	53	0.28	0.7
Cow Kidney	17**	15	27	0.21	0.43
Beef Liver	96	36	120	0.54	2.1

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

*Rounded to 2 s.f.

** Consumption or exposure estimates made with a small number of consumers may not be accurate. Where the number of consumers is less than 60, this should be treated with caution and may not be representative for a large number of consumers.

Table A2: Estimated chronic exposure of foods containing Calcdiol for women of childbearing age (16-49 years).

Food Groups	No. of consumers	Mean consumption (g/person/day)*	P97.5 consumption (g/person/day)*	Mean exposure (µg/kg bw/day)*	P97.5 exposure (µg/kg bw/day)*
Semi-skimmed milk	2083	110	400	1.7	5.7
Whole milk	1333	65	330	1	5
Butter	1736	6.9	25	0.1	0.4
Egg yolk	2128	13	39	0.2	0.63
Salmon	375	22	54	0.34	0.89
Trout	168	22	73	0.3	1
Pork cuts	1406	23	81	0.34	1.3
Pork rind	69	4.3	15	0.064	0.23
Pork liver	68	5.8	19	0.084	0.27
Cow Kidney	17**	3.9	7.4	0.054	0.11
Beef Liver	96	10	35	0.15	0.54

*Rounded to 2 s.f.

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

** Consumption or exposure estimates made with a small number of consumers may not be accurate. Where the number of consumers is less than 60, this should be treated with caution and may not be representative for a large number of consumers.